- Home
- VATE vs UNCY Comparison
VATE vs UNCY Comparison
Compare VATE & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VATE | UNCY |
|---|---|---|
| Founded | 1994 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.2M | 145.3M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VATE | UNCY |
|---|---|---|
| Price | $15.28 | $7.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.67 |
| AVG Volume (30 Days) | 55.7K | ★ 657.7K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,246,000,000.00 | $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $582.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 12.55 | N/A |
| 52 Week Low | $3.75 | $0.47 |
| 52 Week High | $16.71 | $8.74 |
Technical Indicators
Market Signals| Indicator | VATE | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 66.82 | 45.44 |
| Support Level | $4.48 | $7.05 |
| Resistance Level | N/A | $7.78 |
| Average True Range (ATR) | 1.23 | 0.51 |
| MACD | 0.19 | -0.15 |
| Stochastic Oscillator | 77.92 | 21.62 |
Price Performance
Historical ComparisonAbout VATE INNOVATE Corp.
Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments. Its segments include Infrastructure, Life Sciences and Spectrum, and Other segment. Through its subsidiaries it provides fully integrated structural and steel construction services; supports healthcare and biotechnology product development; and operates Over-The-Air (OTA) broadcasting stations across the United States (U.S.) including Puerto Rico.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.